|
AU2013203542A1
|
|
Enhanced cytotoxicity of anti-CD74 and anti-HLA-DR antibodies with interferon-gamma
|
|
AU2011203890A1
|
|
Enhanced cytotoxicity of anti-CD74 and anti-HLA-DR antibodies with interferon-gamma
|
|
EP2496256A2
|
|
Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
|
|
US2008096845A1
|
|
Sphingomyelin therapy of autoimmune disease
|
|
AU2006223000A1
|
|
Methods of treating cancer using PPAR-gamma antagonists
|
|
AU2004242498A1
|
|
Sphingomyelin containing preparation for the enhancement of tumor therapy
|
|
US2006193770A1
|
|
Method of determining cytokine dosage for myelosuppressive state
|
|
AU5727000A
|
|
Alpha or beta emitters attached to fragments in radioimmunotherapy
|
|
AU4972200A
|
|
Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity
|
|
WO0059547A2
|
|
Method of detecting endometriosis
|
|
US6541462B1
|
|
Sphingomyelin enhancement of tumor therapy
|
|
US6649352B1
|
|
Method of evaluating myelosuppressive state
|
|
US6703488B1
|
|
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
